Clin2
NCT06613854Possibly a fitRecruiting

Early combination therapy for type 2 diabetes

Type 2 Diabetes Mellitus (T2DM)

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
90 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • Diagnosed with type 2 diabetes within the past 2 years
  • Age between 18 and 70 years old
  • Currently taking metformin at a daily dose of at least 1500 mg
  • HbA1c (average blood sugar) 8.0% or lower
  • No past use of SGLT2i, GLP-1RA, or DPP-4 inhibitor drugs (like empagliflozin, semaglutide, or sitagliptin)
  • Body mass index (BMI) between 22 and 40

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07272343Recruiting· Phase 4
Semaglutide vs. diet changes for new type 2 diabetes

This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.

Jiangxi, Nanchang
NCT07628985Not yet recruiting· Phase 3
Bofanglutide for type 2 diabetes

This study tests a new medication called Bofanglutide (an injectable drug, similar to others in its class) to see if it can help control blood sugar in adults with type 2 diabetes. It may also help with weight management. Participants will continue taking their current diabetes medication (metformin).

Mexico City, Cuauhtémoc
NCT07187856Not yet recruiting· Phase 2
PG-102 vs placebo and semaglutide for type 2 diabetes

This study tests a new medication called PG-102 against a placebo and an existing medication (semaglutide) to see how well it controls blood sugar in people with type 2 diabetes. It may offer a new treatment option that could help lower your blood sugar levels.

Camberwell, Victoria
NCT06894784Recruiting· Phase 3
Combining two diabetes drugs with an automated insulin pump

This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.

Montreal, Quebec
NCT07139548Not yet recruiting· Phase 3
Comparing two injected drugs for type 2 diabetes

This study compares two injectable medications, RAY1225 and semaglutide, added to your usual diabetes pills, to see how well they control blood sugar and affect weight. It aims to help improve glucose control in people with type 2 diabetes.

Beijing, Heibei
NCT07046273Not yet recruiting· Phase 3
Semaglutide for blood sugar control in type 2 diabetes

This study tests a new medication called semaglutide (similar to Ozempic) in people with type 2 diabetes who are already taking metformin. It aims to see if this medication improves blood sugar control and may also help with weight loss.

Hear when a new Type 2 Diabetes Mellitus (T2DM) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.